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Abstract 
Cavernous sinus syndrome is a rare entity in oncology reported only in occasional case 
reports. Optimal therapy is thus poorly defined with rapidly progressive disease dominating 
the picture. Management includes prompt diagnosis, attempts at stabilization of cranial 
nerve function, and aggressive control of central pain syndrome. Here, we report cavernous 
sinus syndrome secondary to the original squamous cell carcinoma of the lung. With 
common presenting causes of this syndrome being infection, thrombosis or tumor, it might 
seem that metastatic tumor would be expected in a patient with a cancer diagnosis. What 
was not so expected was the extremely rapid progression from mild headache and mild 
trigeminal neuralgia with negative-contrast head CT to a massive, destructive lesion 
involving several skull bones and skull base, only 3 weeks later. In addition, the patient was 
severely immunosuppressed at the completion of induction chemotherapy. Infectious 
processes, although unlikely, were considered, as aggressive cancer therapy (including high-
dose steroids and radiation therapy) had no impact on this disease. Despite accurate 
localization, the aggressive nature of this disease with massive bone destruction and dural 
thickening limited any chance of a durable control. We discuss the process of evaluation, 
diagnosis and treatment of symptoms and the importance of a team approach to best 
palliate these unfortunate patients. 
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Introduction 
Despite being a rare phenomenon, cavernous sinus syndrome is of great clinical 
importance due to its high propensity for developing into a life-threatening disorder [1, 
2]. The cavernous sinus contains the carotid artery, its sympathetic plexus, and the 
oculomotor nerves [cranial nerve (CN) III, IV, and VI]. In addition, the ophthalmic 
branch and occasionally the maxillary branch of CN V traverse the cavernous sinus [3]. 
Signs and symptoms from inflammation to involvement include orbital or facial pain, 
orbital swelling and chemosis (secondary to ophthalmic vein occlusion), fever, 
oculomotor neuropathy, and acute trigeminal neuropathy. Cavernous sinus tumors are 
among the most common causes of cavernous sinus syndrome. Tumors may be 
primary, or invade from adjacent structures, as in lateral extension of pituitary tumors, 
or metastases [4, 5]. 
Here, we present a patient with squamous cell lung cancer, having no metastasis on 
initial diagnosis, developing cavernous sinus syndrome as a site of first recurrence. 
Case Report 
We present a 59-year-old white female diagnosed six months earlier with non-small cell lung 
cancer (stage IIIB). She presented with slightly enlarged mediastinal nodes and pericardial fluid 
cytology positive for malignancy. Her cancer therapy consisted of platinum/Taxol-based induction 
chemotherapy. 
At the end of induction therapy, she presented with a 2-week history of progressively worsening 
headache, hearing loss and severe facial pain, all unilateral, left sided, and resembling acute trigeminal 
neuralgia. (Head CT with contrast was normal 3 weeks prior during workup for these milder 
symptoms.) Current physical exam showed left-sided facial sensitivity to light touch, moderate 
retraction of the left eardrum, and subtle weakness of the left lateral rectus muscle (VI) (see fig. 1, fig. 
2). Head CT with contrast was repeated. Imaging now demonstrated massive destruction of the left 
sphenoid bone with extension to the left mastoid and left frontal bone (roof of left orbit) without any 
brain involvement (see fig. 3, fig. 4). MRI confirmed these findings, with encasement of several CN of 
the left cavernous sinus (fig. 5, fig. 6). 
Pain control was extremely difficult due to acute CN involvement and infiltration of the cavernous 
sinus as well as intractable nausea. 
Our patient began urgent whole brain irradiation (1,500 cGy at 300 cGy per day over 5 days) for 
presumed aggressive metastatic disease. Due to a lack of visible response to therapy, progressive CN 
dysfunction, and a rapid decline in vision, neurosurgical stereotactic biopsy was performed to rule out 
an infectious process as opposed to a neoplasm. Frozen sections revealed squamous cell cancer, 
consistent with original cytology, with little or no radiation effect (see fig. 7, fig. 8). 
Despite high-dose steroids and radiation treatments, CN symptoms rapidly progressed with loss of 
CN III through VIII, all left sided. Repeat MRI showed progressive disease along the base of the skull, 
filling the left cavernous sinus with almost complete encasement of the left optic nerve. After only 2 
weeks from the initial cranial findings, the patient was placed on hospice and PCA pump for pain 
control.  
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Discussion 
The impressive nature of rapidly progressing disease and bone destruction, albeit 
from aggressive malignancy, almost resembled an infectious process and was 
unresponsive to any oncological therapy offered. 
Our patient’s central pain syndrome was difficult to manage [6, 7]. Pain is typically 
constant, though it may be moderate to severe in intensity, and is often made worse by 
touch, movement, emotions, and temperature changes – usually cold temperatures. 
Individuals experience one or more types of pain sensation, the most prominent being 
burning. Acute central pain syndrome related to malignancy often begins shortly after 
the causative injury or damage, and is often difficult to manage. 
Causes of cavernous sinus thrombosis often include infection, but less frequent 
etiologies include aneurysm of the carotid artery, carotid-cavernous fistula, 
meningioma, nasopharyngeal carcinoma, idiopathic granulomatous disorders, and 
tumors – with only two reported cases of metastasis secondary from lung squamous 
cell carcinoma [8, 9]. Since the two cavernous sinuses communicate, involvement of 
one may extend to the other. Early diagnosis is essential and treatment depends on the 
etiology. For infectious causes, broad spectrum antibiotics, drainage of the abscess and 
culture are essential for eradication of the offending organism. Anticoagulation may 
help in cases of primary thrombosis, especially in younger patients. In cases where the 
underlying etiology is secondary to metastasis or tumor, the treatment becomes more 
complex. Effective treatment for such cases has not been well studied nor is it 
substantially effective [10, 11]. 
When cancer metastasizes to bone, considerable pain and deregulated bone 
remodeling occur, greatly diminishing the possibility of a cure [12, 13]. Metastasizing 
tumor cells mobilize and sculpt the bone microenvironment to enhance tumor growth 
and promote bone invasion. This presentation of the development of cavernous sinus 
syndrome is exceptionally unique, and sphenoid bone metastasis arising from 
established primary lung or other malignancies is itself rare. None of the published 
literature addresses the optimal management course or its subsequent impact on the 
quality of life of patients with sphenoid bone metastasis [14–16]. 
Specialists involved in the management of our patient’s diagnosis included those 
from the following fields: radiation therapy/oncology, radiology, ophthalmology, 
neurosurgery, pathology, and pain management. The patient experienced a rapid 
deterioration from fully active, with only mildly symptomatic headaches, to suffering 
from utterly debilitating central pain syndrome and ultimately death in a matter of 3 
weeks. With modern imaging techniques, we are often able to correlate physical exam 
findings with early cavernous sinus involvement. In the case presented here, we could 
see the limitations of CT until the tumor mass had enlarged to a thickness relative to 
dural structures, and at that time bone destruction was evident as well, aiding in the 
diagnosis. In addition, MRI allows better soft-tissue resolution of the critical structures 
in this area of the skull base to establish the recurrence. This case will hopefully aid 
clinicians in evaluating cancer response and being aware of the ‘sanctuary site’ of the 
central nervous system to many active systemic chemotherapeutic agents [17–19]. 
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Fig. 1. Physical findings in our patient. 
 
 
 
Fig. 2. Correlation with cranial nerve and cavernous sinus anatomy. 
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Fig. 3. CT showing soft tissue density surrounding the left sphenoid bone with complete cortical 
destruction and invasion of local structures. 
 
 
 
Fig. 4. CT (bone window) showing massive destruction of the sphenoid bone with extension to the 
left mastoid and frontal bone (roof of orbit). 
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Fig. 5. Illustration of several cranial nerves (III–VI) as they pierce the dura mater to enter the 
cavernous sinus. Note: The ophthalmic nerve (CN II) does not travel through the cavernous sinus. 
Visual symptoms are usually a secondary event due to impaired venous drainage from the eye itself 
leading to either retinal edema or severely increased intraocular pressures. 
 
 
 
Fig. 6. MRI-confirmed soft-tissue component extending into the left cavernous sinus and along the 
dura. There was no intracranial metastatic disease. 
 
  
Case Rep Oncol 2012;5:35–42 
DOI: 10.1159/000335896 
Published online: 
January 13, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
 
41 
 
Fig. 7. HE. 40×. Nests of squamous cell carcinoma show marked nuclear pleomorphism and ample 
eosinophilic cytoplasm. 
 
 
 
Fig. 8. Immunohistochemical stain. 40×. Nests of squamous cell carcinoma are immunoreactive for 
high-molecular-weight cytokeratin CK 5,6. 
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